Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Trial Timeline
Nov 24, 2021 → Jul 23, 2024
NCT ID
NCT04995653About Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo
Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo is a phase 1 stage product being developed by Seres Therapeutics for Allogeneic Hematopoietic Stem Cell Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT04995653. Target conditions include Allogeneic Hematopoietic Stem Cell Transplantation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04995653 | Phase 1 | Completed |
Competing Products
9 competing products in Allogeneic Hematopoietic Stem Cell Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 | Astellas Pharma | Phase 2 | 52 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 51 |
| Denosumab | Amgen | Phase 2 | 51 |
| DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar | Pfizer | Phase 3 | 76 |
| Inotuzumab Ozogamicin + Vincristine Sulfate Liposome | Pfizer | Phase 1/2 | 40 |
| Genotropin (Recombinant Human Growth Hormone) | Pfizer | Phase 1 | 32 |
| immunosuppression | Pfizer | Phase 2 | 51 |
| Mycophenolate Mofetil | Hikma Pharmaceuticals | Pre-clinical | 18 |